Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Abiomed, Inc. ABMD

Set alert

Price alert · ABMD

All alert types
381.02 +381.02 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
17.18B
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
60.77
Beta
0.00
Dividend
0.00
Ex-div date
Earnings
Feb 2, 2023
50-d avg
351.42
200-d avg
291.67
1y target
0.00

6M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 4, 2022Earnings: —; estimate 1.08; surprise —%
  • Oct 12, 2022Rating: Mizuho · — → Buy
  • Oct 31, 2022Downgrade: William Blair · Outperform → Market Perform
  • Oct 31, 2022Downgrade: Piper Sandler · Overweight → Neutral
  • Nov 1, 2022Earnings: —; estimate 1.05; surprise —%
  • Nov 1, 2022Rating: Morgan Stanley · Underweight → Equal-Weight
  • Nov 1, 2022Downgrade: Deutsche Bank · Buy → Hold
Signals (29)
NameDateAgo
MACD: Sell SignalNov 21, 20223 years ago
SMA: BullishNov 1, 20224 years ago
SMA: BullishNov 1, 20224 years ago
RSI: OverboughtNov 1, 20224 years ago
SMA: BearishOct 28, 20224 years ago
SMA: BearishOct 28, 20224 years ago
SMA: BullishOct 25, 20224 years ago
SMA: BullishOct 25, 20224 years ago
MACD: Buy SignalOct 13, 20224 years ago
MACD: Sell SignalOct 12, 20224 years ago
SMA: BearishOct 7, 20224 years ago
SMA: BullishOct 4, 20224 years ago
MACD: Buy SignalOct 4, 20224 years ago
MACD: Sell SignalSep 16, 20224 years ago
SMA: BearishSep 13, 20224 years ago
SMA: BullishSep 8, 20224 years ago
MACD: Buy SignalSep 8, 20224 years ago
SMA: BullishSep 7, 20224 years ago
SMA: BearishAug 26, 20224 years ago
SMA: BearishAug 26, 20224 years ago

Newest 20 of 29.

Analyst view

Consensus: hold

Hold
Price target (mean) 0.00
Ratings (0m) 10 8 buy · 2 hold · 0 sell
  • Strong buy5
  • Buy3
  • Hold2
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 10
  • 1 month ago 10
  • 2 months ago 10
  • 3 months ago 10

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ABMD analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.000.00 – 0.001.130.0%295.37M+13.1%0
Next quarter0.000.00 – 0.001.160.0%308.25M+14.2%0
Current year0.000.00 – 0.000.000.0%1.14B+10.8%0
Next year0.000.00 – 0.000.000.0%1.36B+18.7%0

Upgrades and downgrades

The latest rating changes

ABMD analyst upgrades and downgrades
DateFirmActionFromTo
Nov 1, 2022Morgan StanleyUpgradeUnderweightEqual-Weight
Nov 1, 2022Deutsche BankDowngradeBuyHold
Oct 31, 2022William BlairDowngradeOutperformMarket Perform
Oct 31, 2022Piper SandlerDowngradeOverweightNeutral
Oct 12, 2022MizuhoInitiated—Buy
Oct 9, 2022Piper SandlerMaintained—Overweight
Jul 20, 2022Deutsche BankMaintained—Buy
Jul 14, 2022Morgan StanleyMaintained—Underweight
Apr 5, 2022Wolfe ResearchInitiated—Peer Perform
Feb 3, 2022Morgan StanleyMaintained—Underweight
Feb 3, 2022SVB LeerinkMaintained—Market Perform
Jan 6, 2022Morgan StanleyMaintained—Underweight
Aug 5, 2021SVB LeerinkMaintained—Market Perform
Jul 19, 2021SVB LeerinkMaintained—Market Perform
Jun 17, 2021Deutsche BankInitiated—Buy
Jan 28, 2021Morgan StanleyMaintained—Underweight
Jan 28, 2021SVB LeerinkMaintained—Market Perform
Dec 14, 2020Morgan StanleyMaintained—Underweight
Oct 11, 2020SVB LeerinkMaintained—Market Perform
Aug 6, 2020Morgan StanleyMaintained—Underweight
Aug 6, 2020SVB LeerinkMaintained—Market Perform
May 27, 2020SVB LeerinkReiterated—Market Perform
Apr 30, 2020Morgan StanleyMaintained—Underweight
Apr 30, 2020SVB LeerinkMaintained—Market Perform
Apr 26, 2020SVB LeerinkDowngradeOutperformMarket Perform
Mar 26, 2020Morgan StanleyMaintained—Underweight
Mar 22, 2020Stephens & Co.Maintained—Overweight
Feb 11, 2020Morgan StanleyDowngradeEqual-WeightUnderweight
Dec 16, 2019Morgan StanleyMaintained—Equal-Weight
Oct 28, 2019Raymond JamesDowngradeOutperformMarket Perform